118 related articles for article (PubMed ID: 16383049)
1. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.
Melo MD; Obeid G
J Am Dent Assoc; 2005 Dec; 136(12):1675-81. PubMed ID: 16383049
[TBL] [Abstract][Full Text] [Related]
2. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat.
Aghaloo TL; Kang B; Sung EC; Shoff M; Ronconi M; Gotcher JE; Bezouglaia O; Dry SM; Tetradis S
J Bone Miner Res; 2011 Aug; 26(8):1871-82. PubMed ID: 21351151
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-Induced Osteonecrosis of the Jaws (BIONJ).
Singh M; Gonegandla GS
J Maxillofac Oral Surg; 2020 Jun; 19(2):162-167. PubMed ID: 32346224
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate - related osteonecrosis of the jaws: the point of view of the oral pathologist.
Ficarra G; Beninati F
Clin Cases Miner Bone Metab; 2007 Jan; 4(1):53-7. PubMed ID: 22460754
[TBL] [Abstract][Full Text] [Related]
5. Maxilla Osteonecrosis: a differential diagnosis in patients with metastatic cancer on bisphosphonates.
Smith J; Birkeland AC; McHugh JB; Spector ME
J Case Rep Med; 2016; 5():. PubMed ID: 27347432
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review.
Varun B; Sivakumar T; Nair BJ; Joseph AP
J Oral Maxillofac Pathol; 2012 May; 16(2):210-4. PubMed ID: 22923892
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw after radiation followed by bevacizumab.
Park L; Vasile G; Hensley H; Buckley C
Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762867
[TBL] [Abstract][Full Text] [Related]
8. Medication-related osteonecrosis of the jaws in a patient treated with Pembrolizumab: Report of a case and review of the literature.
Nisi M; Pioli MC; Cinquini C; Izzetti R
Oral Oncol; 2024 Jun; 153():106825. PubMed ID: 38692151
[No Abstract] [Full Text] [Related]
9. Osteoradionecrosis of the Jaws: Clinico-Therapeutic Management: A Literature Review and Update.
Nadella KR; Kodali RM; Guttikonda LK; Jonnalagadda A
J Maxillofac Oral Surg; 2015 Dec; 14(4):891-901. PubMed ID: 26604460
[TBL] [Abstract][Full Text] [Related]
10. Closure of an open wound associated with bisphosphonate-related osteonecrosis of the jaw in a breast cancer patient.
Soolari N; Soolari A
Open Dent J; 2011; 5():163-7. PubMed ID: 22135700
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of bisphosphonate-associated osteonecrosis of the jaws in individuals with rheumatoid arthritis - a systematic review.
Tenório JR; Estanho D; Silva LS; Pintor AV; Magno MB; Cavalcante IL; Andrade BA; Maia LC
Med Oral Patol Oral Cir Bucal; 2023 Dec; 29(3):e390-7. PubMed ID: 38150601
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis caused by Bisphosphonates: a clinical case.
Spinelli D; DE Vico G; Bonino M; Barlattani A; Bollero P; Barlattani A
Oral Implantol (Rome); 2009 Oct; 2(4):26-34. PubMed ID: 23285372
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Lentle B; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Mardini MA; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; Ste-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2009 Mar; 36(3):478-90. PubMed ID: 19286860
[TBL] [Abstract][Full Text] [Related]
14. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
15. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
[TBL] [Abstract][Full Text] [Related]
16. Denosumab-related osteonecrosis of the jaw.
Diz P; López-Cedrún JL; Arenaz J; Scully C
J Am Dent Assoc; 2012 Sep; 143(9):981-4. PubMed ID: 22942143
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
19. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw related to bevacizumab.
Estilo CL; Fornier M; Farooki A; Carlson D; Bohle G; Huryn JM
J Clin Oncol; 2008 Aug; 26(24):4037-8. PubMed ID: 18711196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
